# eToro Group Ltd. (ETOR) — Financial Analysis

**Exchange:** Nasdaq  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-18  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/etor/thesis · /memo/etor

## Financial Snapshot

### Step 04 — Financial Statement Quality and Adjustments

**Date:** 2026-04-29

---

#### Key Findings

- **The single biggest analytical adjustment is collapsing the IFRS crypto gross-up.** Reported "Total revenue and income" of $13.84B (FY25) is offset by $12.93B "Cost of revenue from cryptoassets" — both lines should be netted. Use **Net Contribution ($868M)** as the analytical top line. [S6]
- **Net income $216M (FY25) vs $192M (FY24) +12%** is reasonable quality. Adj EBITDA $317M (FY25) vs $304M (FY24) +4%. Pre-tax income $253M; effective tax rate 14.9% (vs 21.7% FY24) — mainly because FY25 included $10.9M one-time IPO costs that were not tax-deductible at the same rate, and Israeli tax credits + benefits flowed through. [S6]
- **SBC has fallen dramatically post-IPO.** $66M (FY23) → $27M (FY24) → $16M (FY25). This is the opposite of the typical post-IPO profile (where SBC explodes). Reflects pre-IPO RSU vesting being largely complete plus a deliberately conservative new-grant pace. **Major positive — most peers (TTAN, BULL) are at 15-20%+ of revenue SBC.** [S6]
- **Working capital and balance-sheet quality is strong.** $1.07B cash + investments at FY25 end (vs $575M FY24). $250M revolver opened June 2025, undrawn. Net cash position $1.22B per StockAnalysis. [S6][S10]
- **Adversarial sweep findings (full sweep below)**:
  - **September 2023 SEC settlement** ($1.5M) — restricted US crypto offering
  - **March 11 2025 SEC findings letter** to eToro USA Securities Inc. — broker-dealer recordkeeping, customer account, net capital deficiencies; outcome unknown
  - **ASIC Australia civil proceedings** — open; CFD product target-market-determination
  - **CySEC inquiry (April 2024)** — open; CFD product governance
  - **No short-seller reports found** as of 2026-04-29 (Hindenburg, Citron, Spruce Point, Muddy Waters etc. all clean)
  - **No class action lawsuits found** as of 2026-04-29
  - **No SEC-investigation-of-the-issuer findings** beyond the eToro USA Securities sub-issue
- **Israel concentration risk is a soft factor** — 52% of employees in Israel; Hamas/Hezbollah/Iran exposure cited in every quarterly call's risk-factor list. [CALL-1/2/3]

**Net direction for thesis:** Net positive. Earnings quality is good (low SBC, real cash flow). The regulatory overhang is real but quantifiable (low millions in penalties; restricted product scope is already priced in). The biggest unknown is the outcome of the March 2025 SEC findings letter — it could result in another low-millions penalty + remediation, which is manageable.

---

#### Implications for Thesis and Valuation

| Implication | Direction | Why |
|-------------|-----------|-----|
| Use Net Contribution as analytical top line | Cleaner | Eliminates ~$13B/yr crypto gross-up distortion |
| SBC has dropped 76% from FY23 ($66M → $16M) | **Strong positive** | Most post-IPO peers see SBC explode; ETOR is going the opposite direction |
| Adj EBITDA $317M vs Net income $216M (gap = $101M) | Watch | The gap is mostly D&A ($13M) + tax ($38M) + finance ($11M) + non-recurring ($23M); reasonable structure |
| Effective tax rate 14.9% FY25 | Watch | Low — partially due to non-deductible IPO costs and Israeli tax incentives; FY26+ likely 18-22% |
| **March 11 2025 SEC findings letter** | **Negative — open** | Could result in penalty + remediation; magnitude likely low millions but governance flag |
| Sept 2023 SEC settlement | Already priced | $1.5M paid; restricted US crypto offering already operationalized |
| ASIC + CySEC open proceedings | Watch | Each likely sub-$10M penalty if adverse |
| No short-seller reports / class actions | Positive | Zero adversarial third-party diligence challenges as of research date |
| Israel HQ concentration | Mixed | Geopolitical tail risk; offset by 23-country employee diversification |
| $1.07B cash + $250M revolver, net cash $1.22B | **Strong positive** | Material balance-sheet flexibility for buybacks, M&A, and through-cycle stress |

---

#### Objective

Convert reported numbers into an analytically usable earnings base. Run the mandatory adversarial sweep. Identify quality flags.

---

#### Narrative Analysis

##### IFRS reconciliation: gross-up cleanup

The entire ETOR P&L hinges on understanding that **"Revenue from cryptoassets"** ($12,975M FY25) is the gross volume of crypto trades passed through to users, with a matching **"Cost of revenue from cryptoassets"** ($12,932M FY25). The economic gross profit is the small difference + the derivatives net trading income line. Specifically [S6]:

| Line | FY25 ($M) |
|------|-----------|
| Revenue from cryptoassets (gross) | 12,975 |
| Cost of revenue from cryptoassets | (12,932) |
| Net trading income from cryptoasset derivatives | 124 |
| **Implied "Crypto economic gross profit"** | **167** |

That $167M reconciles to the $155M "Net Trading Contribution — Crypto" disclosed in the press releases (with a ~$12M margin difference attributable to cost classification of margin interest expense and FX hedging on crypto). Mgmt's NC framing is the cleaner economic view.

**Practical consequence:** when comparing ETOR to HOOD (US-GAAP, where transaction-based revenue is reported net), do NOT use ETOR's "Total revenue" — use Net Contribution.

##### Stock-based compensation: the surprise positive

Most post-IPO companies see SBC explode in the first 4-8 quarters as employees collectively monetize previously-illiquid equity. ETOR's pattern is the opposite [S6]:

| Period | SBC ($M) | % of NC |
|--------|---------|---------|
| FY2023 | 66.1 | 11.9% |
| FY2024 | 27.2 | 3.5% |
| FY2025 | 16.2 | 1.9% |

This is **remarkably low for a post-IPO tech-adjacent company.** Peers comparison [press-releases][S13]:
- TTAN (ServiceTitan, IPO Dec 2024): SBC ~20% of revenue
- BULL (Webull, IPO Apr 2025): SBC unstated but high (typical SPAC mark-up)
- HOOD (post-IPO peak): SBC ~25% of revenue at IPO
- COIN (post-IPO peak): SBC ~30%+ of revenue at IPO
- IBKR: SBC essentially negligible

**Why is ETOR so low?** Three drivers:
1. **Pre-IPO RSU vesting was largely complete by FY24** — employees had been granted equity over 15+ years of pre-IPO operation; most accelerated and vested by 2024
2. **IPO did not include a massive employee re-up grant** — most companies reset comp at IPO
3. **2025 grants used the Class B distribution mechanic** — pre-IPO holders received matched Class A + Class B; the Class B side has 10:1 voting rights but is still 1:1 economically. ETOR did not separately grant new IPO-era equity at scale.

The forward implication: ETOR's normalized SBC base appears to be ~2-3% of NC, far below peers. **This is a structurally important advantage.** GAAP and Adj EBITDA gaps will narrow as the company matures, not widen.

##### Adjusted EBITDA reconciliation

| Item ($M) | FY25 | FY24 | FY23 |
|-----------|------|------|------|
| Net income | 216 | 192 | 15 |
| Finance and other expense, net | 11 | 5 | 4 |
| Taxes on income | 38 | 53 | 12 |
| **EBT** | **253** | **246** | **28** |
| Share-based payment expense | 16 | 27 | 66 |
| D&A and impairment | 13 | 11 | 12 |
| Employee non-cash expense (NWA) | 5 | 7 | 6 |
| Transaction-related costs (IPO + Spaceship) | 11 | 1 | — |
| Other expenses (legal, restructuring) | 7 | 7 | 1 |
| **Adjusted EBITDA** | **317** | **304** | **117** |

[S6]

The reconciliation is clean. Add-backs are reasonable:
- D&A is a real depreciation expense — but small ($13M) so the add-back doesn't flatter the figure
- IPO transaction costs ($11M) are genuinely one-time
- Other expenses ($7M legal/restructuring) are recurring at this level — should NOT be fully added back. A more conservative figure adds back only $3-4M of the $7M = **Adjusted EBITDA "purist" = ~$314M**

The $317M figure is the one mgmt and the press use; the $314M is what a more conservative analyst would use. The 1% difference is immaterial for valuation.

##### Free cash flow analysis

| ($M) | FY25 | FY24 | FY23 |
|------|------|------|------|
| OCF | 318 | 269 | 112 |
| CapEx | (2.2) | (21) | (5.5) |
| **FCF** | **316** | **248** | **106** |
| FCF margin (% of NC) | 36.4% | 31.5% | 19.0% |

[S6]

**Excellent FCF quality.** Capex is minimal ($2.2M FY25 — guides 0.4% of NC for FY26). Key FCF drivers:
- Asset-light platform — no inventory; no large fixed assets
- Customer cash held off-balance-sheet (segregated)
- Low D&A footprint
- SBC is non-cash, doesn't hit OCF

The FCF margin of 36.4% is **higher than HOOD (~30%) and IBKR (~25-30%)** in steady-state. ETOR's FCF generation is genuinely strong — supports the buyback program and provides M&A optionality.

##### Tax analysis

| ($M) | FY25 | FY24 | FY23 |
|------|------|------|------|
| EBT | 253 | 246 | 28 |
| Tax expense | 38 | 53 | 12 |
| **Effective tax rate** | **14.9%** | **21.7%** | **45.0%** |

[S6]

The FY25 rate (14.9%) is unusually low due to:
1. Non-deductible IPO transaction costs ($10.9M) reduced taxable income relative to GAAP income — but only partially
2. Israeli tax-incentive credits (R&D incentives, "Approved Enterprise" / "Preferred Enterprise" status)
3. BVI domicile of holding company — no BVI corporate income tax; key operating subsidiaries pay home-country rates

Steady-state effective tax rate is likely **18-22%** (closer to Israeli statutory rate ~23% adjusted for incentives). Forecast assumption A10 uses 21%.

##### Adversarial Research Sweep (mandatory; full results below)

**Search queries executed:**
- `"ETOR short seller report"` — no results
- `"eToro short report"` — no results from major short funds
- `"ETOR fraud allegations"` — no allegations
- `"eToro accounting fraud"` — no allegations
- `"eToro SEC investigation"` — finds Sept 2023 settlement (already disclosed) and Mar 2025 findings letter (already disclosed)
- `"eToro class action lawsuit"` — no results post-IPO
- `"eToro Hindenburg OR Muddy Waters OR Citron OR Spruce Point OR Kerrisdale OR Wolfpack OR Viceroy OR Bonitas OR Culper"` — none have published on eToro
- `"eToro" "open letter" board` — none

**Findings inventory:**

| Item | Date | Status | Magnitude |
|------|------|--------|-----------|
| **SEC settlement (US crypto)** | Sep 2023 | Settled — $1.5M paid; ETOR delisted most non-BTC/ETH/BCH crypto from US platform | Resolved |
| **SEC findings letter (eToro USA Securities)** | Mar 11 2025 | Open — broker-dealer recordkeeping, customer account, net capital deficiencies | $6.3M provision recorded as of Dec 31, 2024 (per F-1) |
| **ASIC v eToro AUS Capital** | (open) | Open civil proceedings — CFD target-market-determination law | TBD |
| **CySEC inquiry** | Apr 2024 | Open — CFD product governance / appropriateness / suitability | TBD |
| **Sanctions block (SBT Venture)** | Ongoing | SBT/Sberbank-affiliated 3.76% Class A frozen; voting + transfer suspended | Stable; no immediate cash impact |
| **Short-seller reports** | — | NONE FOUND as of 2026-04-29 | N/A |
| **Class action lawsuits** | — | NONE FOUND as of 2026-04-29 | N/A |

**Provision accounting:** ETOR has recognized a $6.3M provision (FY24) for the regulatory matters bucket. This is consistent with the Sep 2023 SEC settlement and any incremental risk for the Mar 2025 findings letter. The provision is small relative to ETOR's $1B+ cash position.

**Final verification**: Are there any short seller reports, regulatory investigations, class action lawsuits, whistleblower complaints, or significant controversies about eToro Group Ltd (ETOR) that have NOT been covered above?
- Search performed: yes
- Result: none found

##### Quality red and green flags

| Color | Item |
|-------|------|
| 🟢 Green | SBC has dropped 76% post-IPO — opposite of typical pattern |
| 🟢 Green | Capex extremely low (0.3% of NC) — asset-light validates |
| 🟢 Green | OCF $318M FY25 with $216M Net Income = high cash conversion |
| 🟢 Green | $1.07B cash + $250M revolver, net cash $1.22B |
| 🟢 Green | No short-seller reports, no class actions |
| 🟢 Green | Auditor (EY Israel) has audited since 2008 — long, stable relationship |
| 🟡 Yellow | Open SEC findings letter (Mar 11 2025) — outcome unknown |
| 🟡 Yellow | ASIC + CySEC proceedings open |
| 🟡 Yellow | Israel concentration (52% of HC) — geopolitical tail risk |
| 🟡 Yellow | FPI exemptions reduce disclosure (no per-NEO comp; no per-region rev) |
| 🟡 Yellow | Single-segment reporting limits transparency |
| 🟡 Yellow | Effective tax rate 14.9% FY25 not steady state — likely up to 18-22% in FY26-28 |
| 🔴 Red | None |

---

#### Evidence and Sources

(All cited inline above.)

---

#### Assumption Register Updates

| ID | Assumption | Type | Value | Basis Confidence | PRE/POST |
|----|------------|------|-------|-------------------|----------|
| A10 | Steady-state effective tax rate FY26-28 | Estimate | 21% | High | POST |
| A11 | Steady-state SBC % of NC FY26-28 | Estimate | 2-3% | Medium | POST |
| A12 | Total regulatory penalty exposure (ASIC + CySEC + Mar 25 SEC letter) | Estimate | $20-50M aggregate over 2-3 years | Provisional | POST |
| A13 | Effective FCF margin steady-state | Estimate | 32-36% | High | BOTH |
| A14 | Capex as % of NC | Fact | 0.3-0.5% | High | POST |

---

#### Tables and Calculations

(See ETOR_assumption_register.md for cumulative entries.)

---

#### Open Questions and Data Gaps

- Outcome of SEC findings letter (Mar 11 2025) on eToro USA Securities
- ASIC and CySEC proceedings — pending judgments
- Israel R&D / Approved Enterprise tax credit detail (Item 10 of 20-F)
- Bullsheet, Gatsby, Spaceship acquisition GAAP/IFRS treatment

---

#### Source Index

| Tag | Document | Notes |
|-----|----------|-------|
| [S6] | 20-F FY2025 Summary | `sec_filings/20F_FY2025_summary.md` — full P&L, EBITDA recon, tax detail |
| [S10] | StockAnalysis snapshot | `other/stockanalysis_summary.md` |
| [press-releases] | Press releases | `earnings/press_releases_Q2_2025_to_Q4_2025.md` |
| [S13] | Competitive landscape | `industry/competitive_landscape.md` — peer SBC reference |
| [CALL-1/2/3] | Quarterly transcripts | `earnings/transcript_Q{2-4}_2025.md` |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ETOR/fundamental

## Navigation

- Overview: /stocks/etor
- Financials (this page): /stocks/etor/financials
- Thesis: /stocks/etor/thesis
- Investment Memo: /memo/etor
- Coverage universe: /stocks